tbuckley/cabot-search huggingface dataset:
FRI0651 Observational reproducibility study of uco-track©, an automatized measurement of mobility, in patients with axial spondyloarthritis
Authors: J Garrido, E Collantes, J Mulero, B Flores, P Zarco, R Mazzucchelli, M Domínguez-González, L Carmona, L Cea-Calvo, M Arteaga, R Curbelo
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> The classical measures of spinal mobility for the assessment of patients with axial spondyloarthritis (SpA), such as BASMI, are subject to inter-observer variability. <h3>Objectives</h3> We assessed the reproducibility of the UCOASMI index (University of Cόrdoba Ankylosing Spondylitis Metrology Index), a composite index of cervical and spinal mobility obtained with the UCOTrack<sup>©</sup> motion analysis system (an innovative 3D motion capture system based on video-images) [1], in patients with axial SpA. <h3>Methods</h3> An observational study of repeated measures was carried out in 3 Spanish centers with the technology available (H. Reina Sofía, Cόrdoba, H. Puerta de Hierro, Madrid and H. Fundaciόn Alcorcόn, Madrid). For the assessment of intra-observer reliability, 30 patients (10 per center) were evaluated twice, 3–5 days apart. For the inter-observer reliability, 9 patients were evaluated in the 3 centers by 3 observers (window 3–7 days). The Intraclass Correlation Coefficients (ICC) for UCOASMI and classical metrology measurements were calculated. <h3>Results</h3> We included 30 patients (73% men, mean age 52 [SD 9], mean BASDAI 3.3 [SD 2]). The table shows the intra- and inter-observer reliability values. The reproducibility of UCOASMI was very high, with inter-observer ICC 0.99, and intra-observer ICC 0.97, 0.97 and 0.99, higher than most conventional measurements. The Schober test and cervical rotation showed lower reproducibility (inter-observer ICC between 0.58 and 0.68) and variable intra-observer ICC. <h3>Conclusions</h3> The reproducibility of the UCOASMI, obtained through the UCOTrack<sup>©</sup> motion analysis system in the 3 centers, was very high, in contrast to the lower reproducibility of the Schobert test and other measures of classical metrology. The reliability of this system opens the door to using this technology to monitor SpA patients and in future research studies. <h3>References</h3> Garrido-Castro JL, Escudero A, Medina-Carnicer R, et al. Validation of a new objective index to measure spinal mobility: the University of Cordoba Ankylosing Spondylitis Metrology Index (UCOASMI). Rheumatol Int 2014;34:401–6. <h3>Acknowledgements</h3> Funded by MSD, Spain. <h3>Disclosure of Interest</h3> None declared
<i>ANGPTL1</i> Interacts with Integrin α1β1 to Suppress HCC Angiogenesis and Metastasis by Inhibiting JAK2/STAT3 Signaling
Authors: Qian Yan, Lingxi Jiang, Ming Liu, Dandan Yu, Yu Zhang, Yan Li, Shuo Fang, Yan Li, Ying-Hui Zhu, Yun-Fei Yuan, Xin-Yuan Guan
Journal: Cancer Research (2017)

Abstract Downregulation of tumor suppressor signaling plays an important role in the pathogenesis of hepatocellular carcinoma (HCC). Here, we report that downregulation of the angiopoietin-like protein ANGPTL1 is associated with vascular invasion, tumor thrombus, metastasis, and poor prognosis in HCC. Ectopic expression of ANGPTL1 in HCC cells effectively decreased their in vitro and in vivo tumorigenicity, cell motility, and angiogenesis. shRNA-mediated depletion of ANGPTL1 exerted opposing effects. ANGPTL1 promoted apoptosis via inhibition of the STAT3/Bcl-2–mediated antiapoptotic pathway and decreased cell migration and invasion via downregulation of transcription factors SNAIL and SLUG. Furthermore, ANGPTL1 inhibited angiogenesis by attenuating ERK and AKT signaling and interacted with integrin α1β1 receptor to suppress the downstream FAK/Src–JAK–STAT3 signaling pathway. Taken together, these results suggest ANGPTL1 as a prognostic biomarker and novel therapeutic agent in HCC. Cancer Res; 77(21); 5831–45. ©2017 AACR.
AB1144 Good therapeutic response with biologics: remission is reality. data from the austrian bioreg registry
Authors: M Herold, G Eichbauer-Sturm, T Nothnagl, R Puchner, B Rintelen, P Spellitz, BF Leeb
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Remission or at last low disease activity is the aim of drug therapy in patients with chronic inflammatory rheumatic diseases. We evaluated disease activity in patients treated with biologics and using data of the Austrian biologic registry. <h3>Objectives</h3> The aim of this evaluation was to elucidate disease activity in patients with rheumatoid arthritis (RA), spondyloarthritis (SpA) and psoriatic arthritis (PsA) at baseline and at control-visits every six months after inclusion in BioReg. <h3>Methods</h3> Data were extracted from the Austrian BioReg registry (http://www.bioreg.at) which was initiated in 2009 to document patients treated with one of the biologics approved in Austria. Patients with ongoing biologic therapy as well as biologic-naïve patients starting biologic therapy can be included (baseline, BL). Further documentation is recommended about every six months (V1,V2 up to V11). Meanwhile, 1877 patients (rheumatoid arthritis (RA) n=1046, ankylosing spondylitis (SpA) n=446, psoriatic arthritis (PsA) n=322, other disease n=63) have been documented. Estimation of disease activity is done using DAS-28 as well as RADAI-5 in RA, SASPA in PsA, and BASDAI in SpA. <h3>Results</h3> DAS-28 (median values of BL; V1; V2; V9; V10) of patients with RA are 3,30; 2,51; 2,58; 2,52; 2,49, the respective RADAI-5 values are 3,2; 2,4; 2,2; 2.0; 2,3. BASDAI in patients with SpA were 3,60; 2,61; 2,45; 2,63; 2,20. Median values of inflammation9s laboratory markers (ESR in mm/1st hour and CRP in mg/l) were always within the normal range (ESR and CRP in RA 15; 12; 12; 12,5; 14 and 2,0; 2,0; 2,0; 2,0; 2,0; in SpA: 8; 6; 7; 8; 8; and 2,0; 1,4; 1,4; 1,1; 1,0 in PsA 9; 8; 9; 7 (V7); 6 (V8); and 1,6; 1,5; 1,4; 1,9 (V7); 0,8 (V8)). <h3>Conclusions</h3> Our data confirm the efficiency of therapy with biologicals. During 5 years of continuous treatment more than half of patients with RA reach and keep remission with a DAS-28 below 2,6 and normal values of ESR and CRP. Also patients with SpA and PsA show similar successful therapeutic response. <h3>Acknowledgements</h3> BIOREG is supported by an unlimited industrial grant <h3>Disclosure of Interest</h3> None declared
Phase I/II Study on Cytarabine and Idarubicin Combined with Escalating Doses of Clofarabine in Untreated Patients with Acute Myeloid Leukemia and High Risk for Induction Failure (AMLSG 17-10 CIARA)
Authors: Juergen Krauter, Walter Fiedler, Richard F. Schlenk, Peter Paschka, Felicitas Thol, Michael Lübbert, Mohammad Amen Wattad, Mareike Verbeek, Christian Koenecke, Barbara Neuhaus, Maxim Kebenko, Melanie Janning, Konstanze Dohner, Verena I. Gaidzik, Heiko Becker, Christine Greil, Peter Reimer, Katharina Götze, Hartmut Döhner, Arnold Ganser, Michael Heuser
Journal: Blood (2016)
AB0027 Expression density of receptors to TNF-ALPHA is associated with DAS-28 score in rheumatoid arthritis
Authors: AA Alshevskaya, J Lopatnikova, N Shkaruba, O Chumasova, A Sizikov, V Lukinov, A Moskalev, S Sennikov
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> For a number of cytokines and growth factors density of receptors expression has been shown to be important in regulation of action intensity and variation. Although TNF-alpha is actively involved in the development and progression of chronic inflammation in rheumatoid arthritis (RA) role of membrane receptors and their regulatory function in RA remains unclear. <h3>Objectives</h3> To assess associations of membrane-bound receptors expression and soluble receptors and cytokine content with disease activity score in patients with rheumatoid arthritis. <h3>Methods</h3> To reveal linear relationships among integrated score DAS-28 and studied parameters of intact T-cells, B-cells and monocytes (evaluated by flow cytometry) and parameters of mediators soluble content (evaluated by ELISA) building of multiple linear regression model (MLRM) with a standard assessment of the regression coefficients by least squares method were used. To determine receptor number on the cells QuantibritePE Beads (BD) were used. <h3>Results</h3> For the group of patients with acute stage of RA MLRMs with best statistical quality characteristics revealed that for lymphocytes both TNFR1 and TNFR2 number had significant associations with DAS-28; for monocytes only number of TNFR2 was significant. Lower DAS-28 index is associated with higher number of TNFR2 per cell and lower number of TNFR1. Comparison of models with different combinations of studied TNFR-parameters revealed that percentages of cells expressing receptors for TNFα validated not more than 20% of DAS-28 variation, while the number of receptors indicators on cells validated 40–50% of DAS-28 variation. Full MLRM with all 15 studied parameters validated about 70% of DAS-28 variation. For the group of patients with acute stage of RA MLRMs with best statistical quality characteristics revealed that for lymphocytes both TNFR1 and TNFR2 number had significant associations with DAS-28; for monocytes only number of TNFR2 was significant. Lower DAS-28 index is associated with higher number of TNFR2 per cell and lower number of TNFR1. Comparison of models with different combinations of studied TNFR-parameters revealed that percentages of cells expressing receptors for TNFα validated not more than 20% of DAS-28 variation, while the number of receptors indicators on cells validated 40–50% of DAS-28 variation. Full MLRM with all 15 studied parameters validated about 70% of DAS-28 variation. <h3>Conclusions</h3> Number of receptors to TNF-alpha is more associated with RA activity score as compared with soluble receptors or cytokine. Number of receptors type 1 and type 2 to TNF-alpha per cell have opposite influence on disease activity score. Our findings indicate the involvement of receptors expression density changes in the pathological process in RA. <h3>Disclosure of Interest</h3> None declared
New drug targets for chronic cough: research you can literally sink your teeth into!
Authors: Caroline J. Jolley, Surinder S. Birring
Journal: European Respiratory Journal (2017)

Cough is an essential neurally mediated reflex that has evolved to protect the upper airways from obstruction, and to expel chemical and mechanical irritants. When heightened or persistent, however, cough presents a clinically challenging source of considerable physical and psychological morbidity [1, 2]. In the USA, cough continues to be the commonest single symptom for which patients seek a medical consultation [3]. Chronic cough, defined as cough continuing for >8 weeks, is also globally prevalent and accounts for 10% of respiratory referrals to secondary care [4]. Human dental pulp stem cells and endocannabinoids: can preclinical models translate to effective antitussive drugs? <http://ow.ly/RAJL30eq351>
整列した筋芽細胞含有ヒドロゲルのマイクロ流体増強3Dバイオプリンティングはin vitroおよびin vivoで機能的に組織化された筋原線維を誘導する【Powered by NICT】
Authors: Costantini Marco, Testa Stefano, Mozetic Pamela, Barbetta Andrea, Fuoco Claudia, Fornetti Ersilia, Tamiro Francesco, Bernardini Sergio, Jaroszewicz Jakub, Swieszkowski Wojciech, Trombetta Marcella, Castagnoli Luisa, Seliktar Dror, Garstecki Piotr, Cesareni Gianni, Cannata Stefano, Rainer Alberto, Gargioli Cesare
Journal: Biomaterials (2017)
THU0391 Female gender is associated with a poorer response to tnf inhibitors in ankylosing spondylitis
Authors: T Rusman, MT Nurmohamed, JC van Denderen, I Visman, IE der Horst-Bruinsma van
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Limited data are available on the influence of gender and lifestyle factors, such as smoking, alcohol consumption and Body Mass Index (BMI) on disease activity and response to TNF inhibitors (TNFi) in ankylosing spondylitis (AS). <h3>Objectives</h3> This study aimed to determine whether these factors influence age at diagnosis, disease activity and response to TNFi. <h3>Methods</h3> In a prospective study, clinical data (age, gender, C-reactive protein, Ankylosing Spondylitis Disease Activity Score (ASDAS), Bath Ankylosing Spondylitis Disease Activity Score (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI) and Bath Ankylosing Spondylitis Metrology Index (BASMI), smoking, alcohol consumption and BMI) were collected in AS patients from a observational cohort, who started or switched treatment with TNFi. Data were collected at baseline and after 6, 12 and 24 months. Independent T-tests and linear regression analyses were performed to assess the influence of gender and lifestyle factors on age at diagnosis and disease activity. <h3>Results</h3> In total, 312 consecutive AS patients, 34% female, were included with a mean follow-up of 18.9 months. Most patients (172, 55%) showed significant improvement after start of TNFi of whom 86 patients (28%) had a clinically important (ASDAS decrease &gt;1.1) and 86 (26.9%) a major clinical improvement (ASDAS decrease &gt;2.2). BMI was significantly correlated with age at diagnosis (p=0.016; 95% CI: 0.07 – 0.65): an increase of BMI with three points delayed the AS diagnosis with one year. At baseline, smoking and gender were not correlated with the ASDAS, but BASDAI and BASMI were both inversely related to BMI. Male gender was significantly associated with a higher chance at clinical response (improvement of the BASDAI with 50% or a 2 point decrease) to TNFi (p=0.041). At one year follow-up the clinical improvement of males versus females was respectively 62% vs. 43% and at two year follow-up 59% vs. 46%. Males also showed a significantly higher ASDAS improvement after one year of follow-up compared to females (p=0.015). <h3>Conclusions</h3> Significantly less females had a clinical response compared to males after one and two years of TNFi treatment. A higher BMI not only prolonged the time to AS diagnosis up to one year, but also negatively influenced the BASDAI and BASMI scores. Female gender and high body weight should be taken into consideration when the efficacy of TNFi is assessed, by stratifying for these factors in the analysis. <h3>Disclosure of Interest</h3> None declared
AB0094 Migration, colonization and distribution of bone marrow mesenchymal stem cells transplanted in cia rats were traced by green fluorescent protein
Authors: J Hou, K Xu, L Zhang, G Zhang, J Gao, D Ma, J Fan
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> The mechanism of mesenchymal stem cells involved in injury and repair in vivo is not fully understood, so it is difficult to evaluate the effect of stem cells on rheumatoid arthritis. <h3>Objectives</h3> To investigate the migration, colonization and distribution of bone marrow mesenchymal stem cells (BM-MSCs) traced by green fluorescent protein (GFP) in the immune organs and joints of CIA rats, and study the mechanism of MSCs in repairing damage. <h3>Methods</h3> 1.MSCs labeled with GFP was cultured, amplified and identified in vitro. 2.Injected with mixture of II type collagen and complete Freund9s adjuvant into Wistar rats space at 14 days: It was randomly divided into five groups, including early intervention group (n=20), late intervention group (n=20), CIA early control group (n=12), late control group (n=12) and normal control group (n=12).(2) MSCs were injected from tail veins according to the number of 1×10<sup>7</sup>/kg,and the control groups were given equal volume of normal saline. (3) Observe the changes of arthritis index, arthritis swelling degree,and appearance of imageology and pathology. 3.The spleen, thymus, lymph nodes and joint tissues of the rats were made into pathological sections when transplanted at 3, 11, 30 and 42 days.The migration and distribution of the transplanted cells in the immune organs and the inflammatory joints were detected by immunohistochemistry. <h3>Results</h3> 1.(1)The arthritis index and degree of joint swelling in early and later intervention groups were decreased significantly than that of CIA control groups (P&lt;0.05). (2)The early intervention group had lower arthritis index and the degree of joint swelling than the later intervention group (P&lt;0.05). 2.The positive results of GFP was successfully detected by immunohistochemical method in the immune organs and joints of CIA rats, and sustainable for at least 42 days. <h3>Conclusions</h3> 1.MSCs transplanted through tail vein can migrate to the spleen, lymph nodes and thymus and joints,and can be long-term (42 days) colonization in these organizations. 2.The intervention of MSCs for CIA rats was effective, and early intervention effect was better than advanced intervention. <h3>References</h3> Gordon I. A. MacDonald, Andrea Augello, Cosimo De Bar. Role of mesenchymal stem cells in reestablishing immunologic tolerance in autoimmune rheumatic diseases. Arthritis &amp;Rheumatism. 2011 Spe, 63(9): 2547–557. David Guéit, Marie Maumus, Florence Apparailly, Christian Jorgensen &amp; Danièe Noë.Therapeutic mesenchymal stem or stromal cells in rheumatic diseases: rationale, clinicaldata and perspectivesClinical. Investigation. 2011 Sep, 1(9): 1269–1277. <h3>Disclosure of Interest</h3> None declared
AB0169 Evaluation of frequency and type of physical therapy in more than 3400 patients with systemic sclerosis
Authors: D Belz, P Moinzadeh, N Blank, E Siegert, J Henes, M Worm, C Sunderkoetter, M Schmalzing, A Kreuter, C Gunther, L Susok, G Zeidler, I Koetter, U Mueller-Ladner, T Krieg, A Juche, T Schmeiser, G Riemekasten, E Aberer, N Gaebelein-Wissing, JHW Distler, M Sárdy, C Pfeiffer, K Kuhr, N Hunzelmann
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Systemic sclerosis (SSc) is a chronic fibrosing autoimmune disease which leads to severe musculoskeletal dysfunction, disability and contractures. Little is known on the type and extent of physical therapy (PT) prescribed to SSc patients in daily practice. <h3>Objectives</h3> To determine the type and frequency of PT received by SSc patients. <h3>Methods</h3> The data of 3430 clinically well defined SSc patients registered in the database of the German Network for Systemic Sclerosis were analyzed using SPSS. <h3>Results</h3> 48,5% (1662/3430) of the patients were treated with PT. The most frequently used form of PT was lymphatic drainage (23,6%/876), followed by physical exercise therapy (22%/817) and paraffin wax bath (10,5%/389). About half of the patients (46,9%) received two or three different forms of PT simultaneously. The prescription of PT did not correlate with the SSc subtype, as 49,5% (503/1016) of dcSSc patients, 50,3% (850/1689) of lcSSc patients and 45,7% (143/313) of SSc-Overlap patients received PT. PT was significantly more often prescribed to patients with pulmonary fibrosis in 51,1% (617/1208), synovitis in 61,6% (299/485) and CK elevation in 61,1% (174/285) (p=0,001–0,029). PT did not correlate with the extent of skin fibrosis as measured by mRSS. Interestingly, patients with joint contractures (45,5%) (388/853) or tendon friction rubs (40,6%) (114/281) received significantly less often PT (p=0,006/ 0,045). Comparing the prescription of PT during the initial period 2003–2008 (49,1%; 1937/3942) with the follow up period 2009–2013 (45,3%; 2217/4899), a significant decrease of PT prescription was observed (p&lt;0,001). Patterns of PT prescription differed significantly between medical subspecialties (p&lt;0,005) i.e. rheumatologists, dermatologists. <h3>Conclusions</h3> Although SSc is characterized by considerable disability and restriction of motion, less than 50% of patients received PT. The significant decrease in PT prescription during recent years may reflect lack of knowledge how to prescribe PT and more restrictive insurance regulations. <h3>Disclosure of Interest</h3> None declared
AB0460 Use of intravenous immunoglobulin (IVIG) in autoimmune rheumatic diseases: experience in a third level medical center
Authors: M Pérez Cristόbal, R Ricaño Rocha, G Horta Baas, L Barile Fabris, M Portela Hernández
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> IGIV therapy in rheumatology has been used as an alternative treatment for patients with refractory, severe disease, or with contraindication to the use of conventional immunosuppressive therapy as serious infections; it has recently been increased its use to treat multiple autoimmune diseases, however with a limited number of precise indications as there are not enough studies to increase the level of evidence for the administration of IVIG <h3>Objectives</h3> To describe the experience gained with the use of IVIG in autoimmune rheumatic diseases in a third level medical center <h3>Methods</h3> This is an observational, descriptive and retrospective study. We report the use of IVIG in our clinical practice, efficacy and adverse effects. We included consecutive patients with autoimmune rheumatic diseases that received IVIG between 2012 and 2015. The information was extracted from clinical records <h3>Results</h3> We included 35 patients: 19 women, 16 men, 18 with systemic lupus erythematosus (SLE), 15 with autoimmune inflammatory myopathy, 1 with primary Sjögren9s syndrome (SSp) and 1 with polyarteritis nodosa (PAN). The most common indication was active disease associated with severe infection that contraindicated the use of immunosuppressants in 24 patients and in 11 patients refractory activity disease to conventional therapy. The most frequent indications in patients with SLE were: 6 thrombocytopenias, 5 lupus nephritis, 4 pulmonary hemorrhage and 3 neurolupus; of the group of inflammatory myopathy the indications were: 6 dysphagia, 5 respiratory insufficiency and 4 refractory myopathy. In patients with SSp and PAN the indication was peripheral neuropathy. The mean number of IVIG applications was 3.3 (range 1–15). Activity scales were decreased in all patients with IVIG: mean SLEDAI at baseline 15.6 and in the follow up 4.5; in inflammatory myopathies remission was reached in 86% of the cases. The steroid dose was significantly reduced in most patients in the follow up. Four patients had adverse effects associated with IGIV: 2 with tachycardia and hypertension, one with acute pulmonary edema and one with hemolytic anemia. <h3>Conclusions</h3> In our experience, IGIV administration was effective in controlling the activity of the autoimmune rheumatic disease, mainly in patients with concomitant infection, and with a good safety profile. <h3>Discussion</h3> IGIV was an effective alternative treatment in patients with contraindication of conventional treatment or in refractory disease, however it is a high cost treatment and should be used in well selected cases <h3>References</h3> Erwin W. Gelfand, M.D. Intravenous Immune Globulin in Autoimmune and Inflammatory Diseases. N Engl J Med 2012;367:2015–25. Bem Mulhearn I, and Ian N. Bruce. Indications for IVIG in rheumatic disease. Rheumatology 2015; 54: 383–391. <h3>Disclosure of Interest</h3> None declared